Skip to main content
    I

    Insight Molecular Diagnostics Inc. (IMDX)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $1.86
    -0.28 (-13.08%)

    Market Cap: $70.03M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Insight Molecular Diagnostics Inc. (IMDX) Earnings: Report Dates and Results

    Updated Aug 10, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Insight Molecular Diagnostics (IMDX) is expected to report earnings on Mar 24, 2027. In the quarter ended Jun 30, 2026, Insight Molecular Diagnostics reported EPS of -$0.23, in line with the -$0.23 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    26%(9/35)
    Avg Surprise
    -25.42%

    Upcoming Estimates

    Reports Mar 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.24
    Range-$0.24 - -$0.23
    7 analysts
    Revenue Consensus
    $477.16K
    Range$98.00K - $1.16M
    7 analysts

    Next Report

    IMDX has an expected report date of Mar 24, 2027.

    IMDX Earnings Call

    The latest IMDX earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    Earnings History

    Of the 38 quarters below that had an estimate, IMDX beat 11, missed 23 and matched 4. Revenue for the quarter ended Jun 30, 2026 was $239000, down 53.9% from $518000 a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Jun 30, 2026-$0.23-$0.23-$0.23 - -$0.230.00%In lineN/A10 up, 0 downAug 10, 2026$239000
    Mar 31, 2026-$0.12-$0.26-$0.31 - -$0.24+53.85%BeatN/A40 up, 2 downMay 13, 2026$32000
    Dec 31, 2025-$0.72-$0.24-$0.24 - -$0.24-203.16%MissN/A10 up, 0 downMar 26, 2026$1.14M
    Sep 30, 2025-$0.23-$0.24N/A+4.17%BeatN/A10 up, 0 downNov 10, 2025$260000
    Jun 30, 2025-$0.30-$0.24-$0.24 - -$0.24-25.00%MissN/A10 up, 0 downAug 11, 2025$518000
    Mar 31, 2025-$0.23-$0.25N/A+8.00%BeatN/AN/AN/AMay 12, 2025$2.14M
    Dec 31, 2024-$1.93-$1.12N/A-72.32%MissN/AN/AN/AMar 24, 2025$1.49M
    Sep 30, 2024-$0.98-$0.44N/A-122.73%MissN/AN/AN/ANov 12, 2024$115000
    Jun 30, 2024-$0.43-$0.37N/A-16.22%MissN/AN/AN/AAug 8, 2024$104000
    Mar 31, 2024-$2.07-$0.99N/A-109.09%Miss-5275.0%N/AN/AApr 12, 2024$176000
    Sep 30, 2023-$0.62-$0.78N/A+20.51%BeatN/AN/AN/ANov 9, 2023$429000
    Jun 30, 2023-$0.73-$0.59N/A-23.73%MissN/AN/AN/AAug 10, 2023$463000
    Mar 31, 2023$0.04-$0.08N/A+150.00%BeatN/AN/AN/AMay 11, 2023$297000
    Dec 31, 2022-$2.25-$1.60N/A-40.63%MissN/AN/AN/AMar 29, 2023$274000
    Sep 30, 2022-$2.43-$2.33N/A-4.29%MissN/AN/AN/ANov 10, 2022$67000
    Jun 30, 2022-$2.57-$2.00N/A-28.50%MissN/AN/AN/AAug 10, 2022$237000
    Mar 31, 2022-$3.24-$2.00N/A-62.00%MissN/AN/AN/AMay 11, 2022$380000
    Dec 31, 2021-$0.39-$0.12N/A-217.33%MissN/AN/AN/AMar 10, 2022N/A
    Sep 30, 2021-$2.76-$2.00N/A-38.00%MissN/AN/AN/ANov 9, 2021$984000
    Jun 30, 2021-$2.58-$1.84N/A-40.22%MissN/AN/AN/AAug 10, 2021$2.03M
    Mar 31, 2021-$1.00-$1.88N/A+46.81%BeatN/AN/AN/AMay 17, 2021$1.12M
    Dec 31, 2020-$0.09-$0.11N/A+16.28%BeatN/AN/AN/AMar 16, 2021$502000
    Sep 30, 2020-$2.53-$1.84N/A-37.50%MissN/AN/AN/ANov 12, 2020$555000
    Jun 30, 2020-$2.64-$2.05N/A-28.78%MissN/AN/AN/AJul 29, 2020$143000
    Mar 31, 2020-$2.50-$2.12N/A-17.92%MissN/AN/AN/AMay 12, 2020$16000
    Dec 31, 2019-$0.15-$0.09N/A-66.67%MissN/AN/AN/AMar 25, 2020N/A
    Sep 30, 2019-$1.98-$1.64N/A-20.73%MissN/AN/AN/ANov 14, 2019N/A
    Jun 30, 2019-$1.94-$1.72N/A-12.79%MissN/AN/AN/AAug 14, 2019N/A
    Mar 31, 2019-$1.58-$1.72N/A+8.14%BeatN/AN/AN/AApr 1, 2019N/A
    Sep 30, 2018-$1.60-$1.73N/A+7.51%BeatN/AN/AN/ANov 13, 2018N/A
    Jun 30, 2018-$1.89-$1.87N/A-1.07%MissN/AN/AN/AAug 14, 2018N/A
    Mar 31, 2018-$2.51-$2.40N/A-4.58%MissN/AN/AN/AApr 2, 2018N/A
    Sep 30, 2017-$2.53-$2.53N/A0.00%In lineN/AN/AN/ANov 14, 2017N/A
    Jun 30, 2017-$2.60-$2.33N/A-11.59%MissN/AN/AN/AAug 14, 2017N/A
    Mar 31, 2017-$3.25N/AN/AN/AN/AN/AN/AN/AApr 28, 2017N/A
    Dec 31, 2016-$2.00-$2.00N/A0.00%In lineN/AN/AN/AFeb 27, 2017N/A
    Sep 30, 2016-$2.00-$2.00N/A0.00%In lineN/AN/AN/ANov 10, 2016N/A
    Jun 30, 2016-$2.00-$2.13N/A+6.10%BeatN/AN/AN/AAug 11, 2016N/A
    Mar 31, 2016-$2.40-$2.60N/A+7.69%BeatN/AN/AN/AMay 16, 2016N/A
    Dec 31, 2015-$2.88N/AN/AN/AN/AN/AN/AN/AMar 30, 2016N/A
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.48, after -$6.72 the year before. It was -$2.88 for the year ended Dec 31, 2015, the oldest of the 8 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.48N/A
    Dec 31, 2024-$6.72N/A
    Dec 31, 2022-$10.49N/A
    Dec 31, 2021-$6.73N/A
    Dec 31, 2020-$7.76N/A
    Dec 31, 2019-$20.03N/A
    Dec 31, 2016-$8.40N/A
    Dec 31, 2015-$2.88N/A

    Earnings Calls

    The 6 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 3,900 words across 8 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q2Jun 30, 20263,8568
    2026Q1Mar 31, 20263,2597
    2025Q4Dec 31, 20254,8057
    2025Q3Sep 30, 20257,5198
    2025Q2Jun 30, 20256,0629
    2025Q1Mar 31, 20255,0199

    2026Q2 Earnings Call

    Opening remarks

    Gabrielle Woody Investor Relations / Moderator Welcome, everyone, and thank you for joining us to discuss Insight Molecular Diagnostics' second quarter 2026 results. If you have not seen today's shareholder letter, please visit Insight Molecular Diagnostics' Investor Relations page at investors.imdxinc.com. Today's prepared remarks build upon the information already shared in this robust letter. Joining us today are Insight Molecular Diagnostics' President and CEO, Josh Riggs; Chief Science Officer, Ekke Schutz; and CFO, Andrea James. We also have our analysts with us as panelists. After our prepared remarks, our analysts may ask questions. Before turning the call over to Josh Riggs, I'd like to review our safe harbor. The company will make projections and forward-looking statements regarding future events. Any statements that are not historical facts are forward-looking statements. These statements are made pursuant to and within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We encourage you to review the company's SEC filings, including the company's most recent Form 10-K and subsequent Form 10-Q, which identify risks and uncertainties that may cause future actual results or events to differ materially. Please note the forward-looking statements made during today's call speak only to the date they are made, and Insight Molecular Diagnostics undertakes no obligation to update them. And with that, I would like to now turn the call over to Josh Riggs.

    Joshua Riggs President and CEO Thanks, Gabby. It feels great to be coming to you today with line of sight on expected FDA marketing authorization for GraftAssureDx. We have 3 brief but promising takeaways today in our shareholder letter. The first is that after 3 years of rigorous kitted product development, we believe that we are seeing the light at the end of the tunnel on having a regulated product. Back in July, we got our additional information letter from the FDA. It's a normal part of the Class II process where they ask for some additional data and clarification on intended use as part of their review. Since submitting back in March, we've about tripled the amount of samples collected in the study and feel good about addressing all their questions and comments. Prior to submitting our next data package, we are going to have an SIR meeting with the FDA. This meeting is a lot like the Q-Sub process where you get direct and written feedback on your planned approach. It's an opportunity for both parties to make sure there is clear understanding on what is needed to get through to authorization and clear up any potential misunderstandings. Once we have the green light from them, the next steps are pretty straightforward. We package it all up, hit submit and wait for their response.

    Frequently Asked Questions About IMDX

    When is Insight Molecular Diagnostics's next earnings date?

    Insight Molecular Diagnostics's next earnings report is expected for Mar 24, 2027.

    Did IMDX beat earnings estimates last quarter?

    Insight Molecular Diagnostics reported EPS of -$0.23 for the quarter ended Jun 30, 2026, in line with the -$0.23 estimate.

    What EPS do analysts expect from IMDX next quarter?

    The consensus EPS estimate for Insight Molecular Diagnostics for the quarter ending Dec 31, 2026 is -$0.24 from 7 analysts, with estimates from -$0.24 to -$0.23.

    How often does IMDX beat earnings estimates?

    Insight Molecular Diagnostics beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -44.65%.